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Abstract  
The low density lipoprotein (LDL) receptor has been shown to be upregulated in GBM tumor 
cells and is therefore a potential molecular target for the delivery of therapeutic agents.  A 
synthetic nano-LDL (nLDL) particle was developed and tested to determine its utility as a drug 
delivery vehicle targeted to GBM tumors. nLDL particles were constructed by combining a 
synthetic peptide containing a lipid binding motif and the LDL receptor (LDLR) binding domain 
of apolipoprotein B-100 with a lipid microemulsion consisting of phosphatidyl choline, triolein, 
and cholesteryl oleate. Composition analysis, fast protein liquid chromatography, and electron 
microscopy revealed that nLDL was highly reproducible and intermediate in size between high 
density lipoprotein and LDL particles (10.5 ± 2.8 nm diameter).  The binding and uptake of 
fluorescently labeled nLDL particles was assessed using fluorescence microscopy.  Uptake of 
nLDL was time dependent, exhibiting saturation at approximately 3 h, and concentration 
dependent, exhibiting saturation at concentrations greater than 5 µM peptide. Using Lysotracker 
as a cellular marker, nLDL co-localized with lysosomes.  nLDL binding was eliminated by 
blocking LDLRs with suramin and nLDL inhibited binding of plasma LDL to LDLRs.  
Collectively these data strongly suggest that the synthetic nano-LDLs described here are taken 
up by LDLR and can serve as a drug delivery vehicle for targeting GBM tumors via the LDLR. 
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1. Introduction 
Glioblastoma multiforme (GBM) is a highly aggressive malignancy that accounts for 
approximately 85% of primary brain tumors in adults.  Current treatment consisting of surgery, 
radiation and chemotherapy has had limited success and median survival time is approximately 
one year from diagnosis.  A study on seven GBM cell lines showed that these cells have 
upregulated low density lipoprotein receptors (LDLR)s and that receptor numbers per cell varied 
between 125,000 and 950,000 receptors (Maletinska et al., 2000).  Studies on the distribution of 
LDLR in normal rat and monkey brain tissue suggest that normal brain tissue, particularly 
neurons, has relatively low LDLR (Pitas et al., 1987). Thus is appears that the LDLR is a 
potential molecular target for the selective delivery of anti-tumor compounds to GBM.   
 
Low density lipoprotein (LDL) is the major ligand for the LDLR and it is also the major 
transporter of cholesterol in the plasma.  The cholesterol transported by LDL is used for cell 
growth and membrane repair.  LDL is a 22-27 nm particle composed of a core of hydrophobic 
lipids, primarily cholesteryl esters with a small amount of triglyceride, and has a surface coat of 
phospholipids, unesterified cholesterol, and a single molecule of apolipoprotein B-100 (apoB) 
(Grundy, 1990).  ApoB-100 is a 514,000 Dalton glycoprotein with 9 amino acids (3359-3367) 
serving as the binding domain for the LDL receptor (Segrest et al., 2001).  Upon binding to 
LDLR in clathrin coated pits, LDL is internalized via endocytosis and moves into the endosome 
where a drop in pH causes the receptor to dissociate from the LDL. The receptor is recycled back 
to the surface of the cell while the LDL is moved into the lysosome where the particle is 
degraded (Goldstein et al., 1985). This pathway could be useful for the delivery and 
concentration of drugs into tumors expressing LDLR. 
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Tumor cells generally have high cholesterol requirements as they are rapidly dividing cells. 
Increased LDL requirement and receptor activity has been observed in colon cancer (Niendorf et 
al., 1995), prostate tumors (Chen and Hughes-Fulford, 2001),  adrenal tumors (Nakagawa et al., 
1995), hormone unresponsive breast tumors (Stranzl et al., 1997), cancers of gynecological 
origin (Gal et al., 1981), lung tumor tissues (Vitols et al., 1992), leukemia (Tatidis et al., 2002, 
Vitols et al., 1994, Vitols et al., 1984, Ho et al., 1978), and malignant brain tumors (Rudling et 
al., 1990).   It was previously suggested that plasma-derived LDL could be used as a drug 
delivery system for tumors expressing LDLR since its hydrophobic core has the possibility of 
incorporating lipophilic drugs (Firestone, 1994, Rensen et al., 2001). Drugs have been either 
directly loaded onto plasma LDL or the core lipids of LDL were replaced with drugs (Callahan et 
al., 1999, Ji et al., 2002, Chu et al., 2001, Vitols et al., 1985, Firestone et al., 1984, Dubowchik 
and Firestone, 1995, Vitols et al., 1990). Plasma LDL, however, is less than ideal as a targeting 
agent since it is difficult to isolate in large quantities and is variable in composition and size.  
Another approach used reconstituted LDL consisting of a lipid microemulsion containing drugs 
stabilized by purified apoB-100 (Lundberg, 1987, Lundberg, 1994, Lundberg and Suominen, 
1984, Masquelier et al., 2006). The apoB-100 protein is difficult to isolate due to its large size 
and propensity to aggregate and is therefore not useful for generation of large batches of 
reconstituted LDL.  
 
Recent studies have shown the feasibility of creating a synthetic LDL particle as a replacement 
for serum in cell culture media using a lipid microemulsion and a peptide composed of the 
LDLR binding domain of apoB (Baillie et al., 2002, Hayavi and Halbert, 2005).  This synthetic 
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particle was able to support cell growth by delivering cholesterol to cells via the LDL receptor.  
We hypothesized that a synthetic nano-LDL (nLDL) particle that mimics the binding and uptake 
properties of plasma-derived LDL could be useful for targeting GBM cells. In the present report, 
we describe a synthetic nano-LDL particle composed of a lipid microemulsion and a synthetic 
bifunctional peptide which contains a lipid binding domain and the nine amino acid LDLR 
binding domain. We demonstrate that these novel particles mimic the behavior of plasma-
derived LDL and are capable of targeting the LDLR on GBM cells. 
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2. Materials and Methods 
 
2.1. Materials: 
Triolein (TO), cholesteryl oleate (CO), 3,3'-dioctadecyloxacarbocyanine perchlorate (DiO), 
suramin, butylated hydroxytoluene (BHT), and 1% fatty acid free bovine serum albumin (BSA) 
were obtained from Sigma.  Lysotracker Blue DND 22 and 1,1'-dioctadecyl-3,3,3',3'-
tetramethylindocarbocyanine perchlorate (DiI) were obtained from Invitrogen (Molecular 
Probes). Egg yolk phosphatidyl choline (PC) was obtained from Avanti Polar Lipids.  Plasma-
derived LDL and high density lipoprotein (HDL) were obtained from Intracel (Frederick, MD). 
 
2.2. Peptide: 
The peptide used for production of nLDL was a chimera consisting of an 18-amino acid 
amphipathic alpha helix (Anantharamaiah et al., 1985) attached to the LDLR binding domain 
(Segrest et al., 2001).  The complete 29 amino acid peptide sequence is as follows:  
DWLKAFYDKVAEKLKEAFRLTRKRGLKLA.  The underlined region is the LDLR binding 
domain. The peptide was obtained from Biosynthesis Inc. (Lewisville, TX) at greater than 95% 
purity as determined by HPLC analysis. The amino terminus was capped with an acetyl group 
while the carboxy terminus was capped with an amine group. 
 
2.3. Production of synthetic nano-LDL (nLDL):  
Lipid microemulsions were formed using a modification to the method of Baillie et al (2002). The 
microemulsion consisted of PC, TO, and CO combined in a 3:2:1 mole ratio and dried under nitrogen. 
Tris-saline buffer (20 mM Tris, pH 7.2) was introduced into the dried lipids, and the solution was then 
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vortexed for one minute on the high setting. BHT (20μM) was added and the solution sonicated 
(Branson Sonifier) for one hour, at setting 5, on ice, under nitrogen to disrupt large lipid complexes. 
Sonicated particles were spun, 20 minutes at 4000 rpm, to remove particulates. The lipid microemulsion 
was extruded using an Avanti Polar Lipids extruder, 20 times through a 0.1 μm filter and then 20 times 
through a 0.03 μm filter. The final microemulsion was filter sterilized using a 0.22 μm filter. 
Microemulsion was combined with the synthetic peptide at 2.15 μM. The mixture was lightly vortexed 
for 1 minute and then incubated for 30 minutes at room temperature.   Unbound peptide was removed by 
dialysis against Tris-saline buffer at 4°C with two changes at 24 h intervals.  
 
2.4. Size of nLDL particles: 
The size distribution of the synthetic particles was determined by fast protein liquid 
chromatography (FPLC) using a Superose 6 column. The column was connected to an 
Amersham Biosciences FPLC System (Pistcataway, NJ) and equilibrated in Tris-saline buffer 
(pH 7.2). After column equilibration, 0.2 mL of nLDL (approximately 0.15 mg of protein) was 
injected. The sample flow rate was 0.5 mL/min and absorbance was read at 280 nm. Plasma-
derived LDL and HDL were used as standards to calibrate the column.  
 
Ultracentrifugation was utilized to remove lipid-poor particles from the lipid-rich nLDL.  The 
nLDL preparation was adjusted to d=1.21 g/mL and spun for 36 h at 40,000 rpm (4°C) in a 
Beckman Ultracentrifuge using a Ti50.3 rotor.  At the conclusion of the spin, the top 1mL of the 
sample was collected by aspiration and dialyzed against Tris-saline buffer with two buffer 
changes; this fraction constitutes the nLDL fraction used in subsequent experiments. The size of 
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particles was determined by negative staining electron microscopy as previously described (Forte 
and Nordhausen, 1986). 
 
2.5. Composition of nLDL particles:  
Lipid composition of the particles was determined for cholesterol, triglyceride, and phospholipid 
using enzymatic colorimetric assays from Wako (Richmond, VA).  Protein was quantified by the 
Markwell modification of the Lowry Method (Lowry et al., 1951). Compositions of nLDL from 
three separate experiments were carried out to determine reproducibility of lipid and protein 
composition. 
 
2.6. Cell culture:  
Previously described GBM cells lines (SF-767, U-251, SF-763) were obtained from the tissue 
bank of the Brain Tumor Research Center (University of California San Francisco, CA) 
(Callahan et al., 1999).  GBM cells were grown, 37°C, 5% CO2, essentially as described by 
Callahan et al. (1999) in Eagle’s Minimal Essential Medium (MEM) supplemented with 1% 
nonessential amino acids, 1 g/L glucose, 0.292 g/L glutamine, 2.2 g/L sodium bicarbonate, 10% 
fetal bovine serum, and antibiotics until needed for experiments. For most experiments, cells 
were plated at 5x104 cells per well on Lab-Tek II, two-well chamber slides or 12-well plates.  
For confocal microscopy, cells were plated at 2x104 cells on a polylysine coated coverslip in a 
24-well plate.  Cells were allowed to grow for 48 h before lipoprotein-deficient fetal bovine 
serum (LPDS) in above MEM was placed on the cells (Callahan et al., 1999). Experiments were 
conducted on exponentially growing cells, at approximately 70% confluency, 24 h after addition 
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of LPDS media. At the conclusion of each experiment, cells were washed twice with PBS 
containing 1% fatty acid free BSA. 
 
2.7. Fluorescent labeling:  
Fluorescent labeling of the lipid moiety of nLDL with DiO or DiI was carried out essentially as 
described by Pitas et al (Pitas et al., 1981, Innerarity et al., 1986). After labeling, unbound 
fluorescent marker (DiI or DiO) was removed by ultracentrifugation prior to binding and uptake 
experiments. For studies with fluorescently labeled peptide, the peptide was labeled with a 
fluorescein isothiocyanate (FITC) at the N-terminus of the peptide (Biosynthesis, Inc).  
 
2.8. Fluorescence Microscopy: 
Fluorescence microscopy experiments were carried out in 2-well chamber slides using a Zeiss 
200M Axiovert optical microscope.  Digital images were captured with Image Pro Software. 
Cells were fixed in 4% paraformaldehyde in PBS after the PBS rinses.  For nLDL uptake 
experiments which were carried out at 37°C, cells were fixed for 15 min at room temperature.  
For nLDL surface binding experiments which were carried out at 4°C, cells were fixed for 20 
min at 4°C.  Fluorescent images were obtained at 40X magnification. 
 
2.9. Confocal Microscopy: 
Confocal microscopy on dual labeled nLDL (FITC and DiI) was carried out for live and fixed 
cells on glass coverslips using a Zeiss 510 UV/Vis Meta microscope.  Lysotracker Blue (5μM) 
was added to cells at the start of the experiment.  At the conclusion of the experiment, the 
coverslip was washed four times with PBS.  For live cells, the coverslip was mounted onto a 
   
 10
glass slide and sealed.  For fixed cells, fixation was carried out as above and then the coverslip 
was mounted on a glass slide and sealed.  Cells were viewed at 100X magnification.   
 
2.10. Fluorescence activated cell sorting (FACS) analysis:   
FACS experiments were carried out in 12-well dishes.  Cells were incubated with DiO-labeled 
sLDL at various concentrations and for various periods of time as indicated in the figure legends. 
At the conclusion of each experiment, cells loaded with DiO-labeled nLDL were washed with 
PBS and trypsinized.  Cells were centrifuged to remove the trypsin and then resuspended in PBS.  
A Becton Dickinson FACSCaliber instrument was used to assess DiO fluorescence. 10,000 cells 
per well were excited at 488 nm and fluorescence was detected at 530 nm.  Control cells without 
DiO-nLDL were used to correct for nonspecific cellular fluorescence.    
 
2.11. Statistics:  
One way analysis of variance (ANOVA) was used to determine differences in cellular uptake of 
DiO-labeled nLDL.  P-values less than 0.05 were considered significant.  Pair-wise differences 
were assessed using the Tukey follow-up test.  
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3.  Results 
 
3.1. Characterization of nLDL:   
The 29 amino acid bifunctional peptide was observed to be highly water soluble and readily 
bound to lipid microemulsions.  Unbound peptide was removed by dialysis; the amount of 
original peptide remaining bound to nLDL was 82 ± 9% (n=11).  FPLC analysis of the nLDL 
(Figure 1) indicated particles were primarily intermediate between LDL and HDL in size. In 
addition, lipid-poor particles smaller than HDL (fractions 17-19) were also observed.   
 
In order to remove lipid-poor peptide complexes from the lipid-rich particles, nLDL were 
ultracentrifuged at d=1.21 g/mL and the fraction with density ≤ 1.21g/mL isolated and used in all 
cell experiments. This resulted in 28 ± 7% (n=3) recovery of the peptide in the d≤ 1.21g/mL 
fraction. Composition of the centrifugally isolated lipid-rich nLDL (d≤ 1.21g/mL fraction) was:  
peptide, 24 ± 3%; PC, 23 ± 3%; TO, 50 ± 3%, and CO, 3 ± 1% (n=3).  The composition of the 
buoyant nLDL particles is consistent with particles in the LDL-HDL size range.  Electron 
microscopy of the isolated nLDL (Figure 1 inset) revealed that the particles had a mean diameter 
of 10.5 ± 2.8 nm.  
 
3.2. 4°C Binding of nLDL to the LDL Receptor: 
Cell binding experiments were carried out at 4°C to determine whether nLDL bound to LDLR on 
the surface of GBM cells.  A representative micrograph shown in Figure 2B revealed DiI-labeled 
nLDL bound to the surface of SF-767 cells.  A similar distribution of binding is observed for the 
binding of DiI-labeled plasma-derived LDL in SF-767 GBM cells (Figure 2D).  Cell binding was 
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repeated with the U-251 and SF-763 GBM cell lines and yielded a similar binding distribution 
(data not shown).  In the presence of 10mM suramin, an inhibitor of LDL interaction with 
LDLR, the binding of DiI-nLDL is blocked (Figure 3A-B), as was previously observed with 
plasma-derived LDL (Schneider et al., 1982).  This suggests that nLDL is binding to the LDLR.  
Addition of excess unlabeled nLDL to the SF-767 cells competes with plasma-derived LDL for 
receptor binding and greatly reduces the binding of DiI-labeled plasma-derived LDL to the cell 
surface (Figure 3C-D), which further supports the premise that nLDL binds to the LDLR.  
 
3.3. 37°C Uptake of nLDL: 
Uptake of the DiI-labeled nLDL particles by SF-767, U-251, and SF-763 GBM cell lines was 
assessed by incubating cells at 37°C for 1, 3, 6, and 9 hours (1.5 μM peptide) prior to carrying 
out fluorescence microscopy.  A representative fluorescence microscopy photo series of the SF-
767 tumor cell line is shown in Figure 4A.  DiI-labeled nLDL uptake increases between 1 and 3 
hours and appears to saturate at the latter time point.  The U-251 and SF-763 cells showed a 
similar pattern of uptake and saturation (data not shown).   Time dependence of nLDL uptake 
was verified by quantifying uptake of DiO-labeled nLDL (1.5 μM peptide) using FACS analysis.  
Figure 4B indicates that nLDL uptake by SF-767 cells saturates between 3 and 6 hours, 
consistent with the microscopy data.    
 
The concentration dependence of nLDL uptake by SF-767 cells was assessed with DiO-labeled 
sLDL over a range of 0.1μM to 10μM peptide.  Fluorescence was quantified using FACS 
analysis.  Figure 4C indicates a saturability of nLDL uptake at higher concentrations of peptide.   
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3.4. Co-localization of Peptide and Lipid in SF-767 Cells: 
Confocal microscopy was utilized to determine whether the lipid and peptide moieties of nLDL 
co-localize in SF-767 cells (Figure 5).  Dual labeled nLDL particles using FITC to label the 
peptide and DiI to label the lipid were incubated with cells for 3 h at 37°C. Figures 5A-B 
represent fixed cells and demonstrate that the peptide and lipid have both entered cells and 
appear to co-localize.  Similar results are obtained for living cells after 1 h incubation at 37°C 
(Figure 5C-E).  Comparison of images in Figures 5C, D, and E suggest that both peptide and 
lipid co-localize in unfixed cells. Lysotracker Blue was used to identify lysosomes and the 
comparison of Figure 5F with Figures 5C-D suggests that endocytosed peptide and lipid are 
found in the lysosomes.  This is further evidence of receptor-mediated uptake of the nLDL 
particles.   
 
3.5. Comparison of nLDL Uptake by SF-767, SF-763, and U-251 Cells: 
It was previously observed that different GBM cell lines have variable numbers of LDL 
receptors per cell (Maletinska et al., 2000).  To determine whether cell receptor number 
influenced nLDL uptake, three GBM cell lines SF-763, SF-767, and U-251 cells having 950,000, 
288,000, and 128,000 receptors per cell, respectively, were examined. Differences in nLDL 
uptake were quantified using FACS analysis on DiO-labeled nLDL incubated with cells for 3 h 
at 1.5 μM peptide.  Figure 6 shows that U-251 cells take up significantly less fluorescently 
labeled nLDL than SF-767 and SF-763 cells. On the other hand, there was a small but significant 
difference in nLDL uptake between SF-767 and SF-763 cells where the latter show slightly 
higher uptake.  
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4. Discussion 
 
High-grade gliomas are difficult to treat since they grow aggressively and islets of cells often 
remain after surgical excision of the tumor.  These residual cells lead to recurrence of the tumor.  
In recent years the emphasis for treatment of gliomas, as well as other types of tumors, has been 
the identification of specific molecular targets for the delivery of drugs.  Such molecular targets 
would minimize toxic effects on surrounding normal tissue.  The epidermal growth factor 
receptor (Barth et al., 2002), platelet derived growth factor receptor (Hermanson et al., 1992), 
fibroblast growth factor receptor (Morrison et al., 1994), human epidermal receptor type 2 
(Mineo et al., 2004), and interleukin-13 receptor (Mintz et al., 2002) have been shown to be up-
regulated in glioma cells. We have previously shown that human GBM cell lines express high 
levels of LDL receptors (Maletinska et al., 2000) and demonstrated that boronated protoporphryn 
is delivered to the SF-767 GBM cell line by LDL (Callahan et al., 1999).  LDL receptors are 
sparse in normal brain tissue (Pitas et al., 1987) suggesting that the LDL receptor represents a 
unique target that can be used for delivery of chemotherapeutics targeted to tumor cells.  ApoB-
100 on the surface of the LDL is the ligand for the receptor.  However, because plasma-derived 
LDL cannot be obtained in large quantities and the apoB-100 protein is difficult to work with, 
the use of synthetic particles made with small proteins or peptides is desirable.   
 
To generate a synthetic nano-LDL, our approach utilized a bifunctional peptide that possesses 
the LDL binding domain linked to an 18 amino acid amphipathic alpha helix previously 
described by Anantharamaiah et al (1985). This amphipathic helix avidly binds to lipid thus 
stably anchoring the LDLR ligand on the surface of the lipid microemulsion.  Because of the 
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amphipathtic nature of the peptide, it is highly soluble in aqueous medium but readily binds to 
lipid microemulsion.  This approach is different from that of Baille et al (2002) who used only 
the LDLR binding domain capped with retinoic acid and cholesterol; the peptide was not soluble 
in aqueous medium.   
 
We have shown that the nLDL formed with the bifunctional peptide has the ability to recognize 
the LDLR which is a prerequisite for targeted delivery of drugs to cells overexpressing the 
LDLR.  Synthetic nLDL bound to the surface of GBM cells and binding could be blocked by 
suramin (Schneider et al., 1982), a molecule that inhibits LDL-LDLR interactions.  The nLDL 
also was effective in competing for the LDLR in experiments with plasma-derived LDL and 
drastically reduced LDL binding to the receptor. Both of these characteristics are consistent with 
the specific binding of nLDL to LDLR.  Synthetic nLDL uptake using dual labeled particles, i.e., 
fluorescently labeled lipid and fluorescently-labeled peptide, indicated that both moieties co-
localize in the cell.  This also provides evidence that the particles enter cells intact.   The use of 
Lysotracker established that the nLDL particles trafficked to the lysosome as expected for 
LDLR-mediated uptake of particles (Goldstein et al., 1985). In this regard, our results are similar 
to the findings of Callahan et al. (1999) who showed that boronated protophorphyrin introduced 
into SF-767 cell cultures localized in the lysosome and that uptake of the pro-drug required both 
the presence of serum LDL and cell surface LDLR.  
 
The present studies with nLDL suggest that uptake of targeted LDL-like particles is dependent 
on the number of receptors on the cell surface.  As previously reported, the number of LDLR in 
GBM cell lines tested in our study ranged from 125,000 per cell for U-251 cells to 950,000 for 
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SF-763; the SF-767 cell had intermediate numbers of receptors (288,000) (Maletinska et al., 
2000). Accumulation of fluorescently labeled nLDL in both SF-763 and SF-767 was twice that 
of U-251 cells.  However, although SF-763 cells have approximately 3-times the number of 
LDLR per cell than SF-767 cells, their accumulation was only 6% greater than that of SF-767.  
This can be explained, in part, by the observation of Maletinska et al (2000) that the LDLR 
binding affinity of SF-767 cells is much greater than that for SF-763 cells. Additionally, there 
could be differences in LDLR internalization and recycling rate that could account for the 
relatively lower accumulation of nLDL in SF-763 cells.   
 
Plasma LDL and HDL particles are not found in cerebral spinal fluid (Roheim et al., 1979, Pitas 
et al., 1987) because they do not cross the blood-brain barrier.  Since systemic delivery would 
limit the effective distribution of nLDL, the particles can be delivered by convection enhanced 
delivery techniques (Hall et al., 2003) directly to the region of the tumor.  Since nLDL particles 
formed with our bifunctional peptide are small nano-particles (~10.5 nm) it is likely that their 
diffusion will be more optimal than plasma LDL since there is an inverse relationship between 
particle size and its diffusion in tissue.  Because of their hydrophobic core, the nLDLs are 
expected to provide a mechanism for the transport of hydrophobic drugs. In addition, hydrophilic 
drugs can be converted to hydrophobic pro-drugs by chemical modifications as suggested by 
several laboratories (Lundberg et al., 2003, Firestone et al., 1984, Dubowchik and Firestone, 
1995) thus increasing the arsenal of drugs that can be potentially targeted to GBM via nLDL.  
The bifunctional peptide-engineered synthetic nLDL is a promising approach for targeting anti-
cancer drugs to GBM. 
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Figures Legends: 
 
Figure 1:  Fast protein liquid Chromatography of nLDL. There is a large component of nLDL 
particles intermediate in size between plasma LDL and HDL particles; lipid-poor component is 
visible in fractions 17-19.  Electron microscopy (inset) revealed particles 10.5 ± 2.8 nm diameter.   
 
Figure 2: Representative images of cell surface binding of DiI-labeled nLDL and plasma-derived 
LDL.  (A) bright field image of cells and (B) corresponding fluorescence image of DiI-labeled 
nLDL (1.5 μM peptide), (C) bright field image and (D) corresponding fluorescence image of 
DiI-labeled plasma-derived LDL (10μg/mL protein). Experiments were carried out at 4°C for 3 
h. The punctate distribution of DiI-labeled nLDL on the cell surface is similar to that of plasma- 
derived LDL.  This experiment was repeated three additional times with separate nLDL batches 
and yielded similar results. 
 
Figure 3:  Binding of nLDL to LDLR of SF-767 cells. Cells were incubated with DiI-labeled 
nLDL (1.5 μM peptide) in the absence (A) and presence (B) of 10 mM suramin.  Presence of 
suramin inhibits binding of DiI-labeled nLDL to cells.  Cells were incubated with DiI-labeled 
plasma-derived LDL (0.5 μg/mL protein), (C), and competed with 100-fold excess of nLDL, (D).  
Excess nLDL blocks the binding of plasma-derived LDL.  All experiments were carried out at 
4°C for 1 h.   
 
Figure 4:  Representative experiments illustrating that nLDL uptake by SF-767 cells is time and 
concentration dependent. (A) Fluorescence microscopy shows uptake of DiI-labeled nLDL (1.5 
D 
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μM peptide) is time dependent. Uptake of DiI-labeled lipids was tested at 1, 3, 6, and 9 h.  SF-
767 cells were fixed with 4% paraformaldehyde at each time point prior to microscopy. The 
experiment was repeated with a separately produced batch of nLDL and yielded identical results.   
(B) FACS analysis data indicate that uptake of DiO-labeled nLDL (1.5 μM peptide) is time 
dependent.  SF-767 cells were incubated for 1, 3, 6, and 9 h at 37°C with nLDL particles 
previously labeled with DiO.  Data represents mean ± SD of three separate wells.   (C)  FACS 
analysis data show uptake of DiO-labeled nLDL particles is concentration dependent.  Cells were 
incubated for 3 h at 37°C with varying concentrations of nLDL particles (0.1, 1, 5, 10 μM 
peptide) that had been previously labeled with DiO.  Data represents mean ± SD of three 
separate wells.  The data suggests saturation at approximately 5 μM peptide.   This experiment 
was repeated two additional times with separate nLDL batches and yielded identical results.   
 
 
Figure 5:  Confocal microscopy of SF-767 cells reveals colocalization of peptide and lipid in 
lysosomes.  The representative images in A and B were obtained from cells fixed after 3 h 
incubation of cells with dual-labeled nLDL (1.5 µM peptide) where the peptide carried the FITC 
label and lipid the DiI label; (A) FITC label of peptide, and (B) DiI-label in lipids.  The 
representative images in C-F were obtained from living SF-767 cells after 1 h incubation with 
dual labeled nLDL (1.5 µM peptide); (C) FITC-labeled peptide, (D) DiI-labeled lipids, (E) 
images in C and D merged to show co-localization of peptide and lipid and (F) Lysotracker Blue 
image for localization of lysosome reveals co-localization of the peptide and lipid in lysosomes.    
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Figure 6: Uptake of DiO-labeled nLDL is dependent on LDL receptor number.  Cells were 
incubated for 3 h at 37°C with nLDL (1.5 μM peptide) previously labeled with DiO. At the 
conclusion of the experiment, cells were trypsinized and resuspended in PBS.  Data for each time 
point represent the mean ± SD of three separate wells.  Significant differences in fluorescence 
were present for all pairwise comparisons (p<0.05).  This experiment was repeated using a 
separate batch of nLDL and yielded similar results.  
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